These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34739831)

  • 1. The American stem cell sell in 2021: U.S. businesses selling unlicensed and unproven stem cell interventions.
    Turner L
    Cell Stem Cell; 2021 Nov; 28(11):1891-1895. PubMed ID: 34739831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US businesses engaged in direct-to-consumer marketing of perinatal stem cell interventions following the Food and Drug Administration's enforcement discretion era.
    Turner L; Wang JC; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Sahrai V
    Cytotherapy; 2024 Apr; 26(4):393-403. PubMed ID: 38340106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study: Business Booms for Unlicensed and Unproven Stem Cell Treatments.
    Rubin R
    JAMA; 2022 Feb; 327(5):414-415. PubMed ID: 35019946
    [No Abstract]   [Full Text] [Related]  

  • 7. Texas H.B. 810: Increased Access to Stem Cell Interventions or an Increase in Unproven Treatments?
    Matthews K; Kunisetty B; Sprung K
    Stem Cells Dev; 2018 Nov; 27(21):1463-1465. PubMed ID: 30122128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy claims made by US businesses marketing purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Oct; 18(10):781-793. PubMed ID: 37795701
    [No Abstract]   [Full Text] [Related]  

  • 9. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
    Turner LG
    Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
    [No Abstract]   [Full Text] [Related]  

  • 10. Direct-to-consumer marketing of stem cell interventions by Canadian businesses.
    Turner L
    Regen Med; 2018 Sep; 13(6):643-658. PubMed ID: 30255734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory claims made by US businesses engaged in direct-to-consumer marketing of purported stem cell treatments and exosome therapies.
    Turner L; Martinez JR; Najjar S; Arachchilage TR; Sahrai V; Wang JC
    Regen Med; 2023 Nov; 18(11):857-868. PubMed ID: 37867326
    [No Abstract]   [Full Text] [Related]  

  • 12. Characterizing Direct-to-Consumer Stem Cell Businesses in the Southwest United States.
    Frow EK; Brafman DA; Muldoon A; Krum L; Williams P; Becker B; Nelson JP; Pritchett A
    Stem Cell Reports; 2019 Aug; 13(2):247-253. PubMed ID: 31378670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study Shows Businesses Selling Unapproved Stem Cell Treatments Have Turned to Long COVID.
    Eastman Q
    JAMA; 2023 Dec; 330(24):2326-2327. PubMed ID: 38019493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cells. U.S. regulation of stem cells as medical products.
    Sipp D; Turner L
    Science; 2012 Dec; 338(6112):1296-7. PubMed ID: 23224541
    [No Abstract]   [Full Text] [Related]  

  • 15. Businesses marketing purported stem cell treatments and exosome therapies for COVID-19: An analysis of direct-to-consumer online advertising claims.
    Turner L; Martinez JR; Najjar S; Rajapaksha Arachchilage T; Wang JC
    Stem Cell Reports; 2023 Nov; 18(11):2010-2015. PubMed ID: 37890484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tobacco products sold by Internet vendors following restrictions on flavors and light descriptors.
    Jo CL; Williams RS; Ribisl KM
    Nicotine Tob Res; 2015 Mar; 17(3):344-9. PubMed ID: 25173777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mapping and driving the stem cell ecosystem.
    Knoepfler PS
    Regen Med; 2018 Oct; 13(7):845-858. PubMed ID: 30289055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical societies, patient education initiatives, public debate and marketing of unproven stem cell interventions.
    Weiss DJ; Turner L; Levine AD; Ikonomou L
    Cytotherapy; 2018 Feb; 20(2):165-168. PubMed ID: 29239793
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Teaching non-FDA approved nonprescription products: Educating students about potential risks and liability.
    Van Dusen V; Pray WS
    Curr Pharm Teach Learn; 2019 Jul; 11(7):655-657. PubMed ID: 31227086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.